DGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Quest Diagnostics Inc (DGX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong financial growth, positive hedge fund activity, and favorable technical indicators. While there are no recent news catalysts, the company's solid fundamentals and analyst support make it a compelling choice for long-term investment.
The technical indicators for DGX are generally bullish. The MACD is positively expanding, the RSI is neutral at 50.814, and the moving averages are bullish with SMA_5 > SMA_20 > SMA_200. The stock is trading near its pivot level of 197.074, with resistance at 200.233 and support at 193.915.
Hedge funds are significantly increasing their positions, with a 1536.08% increase in buying activity over the last quarter.
SwingMax sent an entry signal on 2026-03-25, and the stock has since gained 0.38%.
Strong financial performance in Q4 2025, with revenue up 7.06% YoY, net income up 11.36% YoY, and EPS up 14.21% YoY.
Analysts have raised price targets, with several firms maintaining positive ratings and projecting upside.
Gross margin dropped by -1.45% YoY in Q4
No recent news or event-driven catalysts to drive immediate price movement.
Quest Diagnostics reported strong financials in Q4 2025. Revenue increased by 7.06% YoY to $2.806 billion, net income rose by 11.36% YoY to $245 million, and EPS grew by 14.21% YoY to 2.17. However, gross margin declined slightly by -1.45% YoY to 31.25%.
Analysts are generally positive on DGX. Recent updates include Evercore ISI lowering the price target to $210 but adding the stock to its 'Tactical Outperform' list. Other firms, such as Mizuho, Baird, and Jefferies, have raised price targets, with Jefferies highlighting strong Q4 results and growth potential. The consensus view supports long-term growth and valuation upside.
